nach oben

Die Urologie

Erschienen in:

01.01.2011 | Leitthema

Medikamentöse Therapiemöglichkeiten des Oligo-Astheno-Teratozoospermie-Syndroms

verfasst von: Dr. M. Trottmann, F.M. Köhn, M. Dickmann, C.G. Stief, A.J. Becker

Erschienen in: Die Urologie | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die medikamentösen Therapiemöglichkeiten des Oligo-Astheno-Teratozoospermie- (OAT-)Syndroms sind vielschichtig. Als klassische Indikationen kommen hierbei hormonelle Störungen sowohl auf hypothalamischer, als auch auf hypophysärer Ebene sowie (sehr viel seltener) die Hyperprolaktinämie in Frage. Weiter gut medikamentös behandelbar sind v. a. akute oder chronische urogenitale Infektionen und Ejakulationsstörungen. Weil häufig keine Ursache für das OAT-Syndrom gefunden werden kann, wird v. a. bei diesen Patienten seit Jahrzehnten mit unterschiedlichen medikamentösen Ansätzen eine Verbesserung der Ejakulatqualität versucht. Die Gabe von Antiöstrogenen, Antioxidantien, Hormonen und Spurenelementen ist in diesem Zusammenhang zu erwähnen. Die Studienlage hierzu ist aber diskrepant und muss kritisch bewertet werden. Dieser Artikel versucht eine Übersicht der aktuellen medikamentösen Therapieoptionen zu geben, erfolglose frühere Anwendungen zu nennen und einen Blick in zukünftige Konzepte zu werfen.

Tüttelmann F, Nieschlag E (2009) Nosologie andrologischer Krankheitsbilder. In: Nieschlag E, Behre HM, Nieschlag S (Hrsg) Andrologie. Grundlagen und Klinik der reproduktiven Gesundheit des Mannes, 3. Aufl. Springer, Berlin Heidelberg New York, S 90–96

Kliesch S (2010) Testosteron und Infertilität. Urologe A 49:32–36CrossRefPubMed

Matsumoto AM (1994) Hormonal therapy of male hypogonadism. Endocrinol Metab Clin North Am 23:857–875PubMed

Kliesch S, Behre HM, Nieschlag E (1994) High efficacy of gonadotropin or pulsatile gonadotropin-releasing hormone treatment in hypogonadotropic hypogonadal men. Eur J Endocrinol 131:347–354CrossRefPubMed

Büchter D, Behre HM, Kliesch S et al (1998) Pulsatile GnRH or human chorionic gonadotropin/human menopausal gonadotropin as effective treatment for men with hypogonadotropic hypogonadism: A review of 42 cases. Eur J Endocrinol 139:298–303CrossRefPubMed

Knuth UA, Hönigl W, Bals-Pratsch M et al (1987) Treatment of severe oligozoospermia with hCG/ hMG. A placebo-controlled double-blind trial. J Clin Endocrinol Metab 65:1081–1087CrossRefPubMed

Vandekerckhove P, Lilford R, Vail A et al (2007) WITHDRAWN: Bromocriptine for idiopathic oligo/asthenospermia. Cochrane Database Syst Rev 18:CD000152

Lähteenmäki A, Räsänen M, Hovatta O (1995) Low-dose prednisolone does not improve the outcome of in-vitro fertilization in male immunological infertility. Hum Reprod 10:3124–3129CrossRefPubMed

Bohring C, Krause W (2005) The role of antisperm antibodies during fertilization and for immunological infertility. Chem Immunol Allergy 88:15–26CrossRefPubMed

10.

Haidl G, Köhn FM, Schill WB (2000) Drug treatment of male fertility disorders. Asian J Androl 2:81–85PubMed

11.

Dohle GR, Diemer T, Giwercman A et al (2010) Guidelines on male infertility. European Association of Urology, Arnheim

12.

Barkay J, Harpaz-Kerpel S, Ben-Ezra S et al (1984) The prostaglandin inhibitor effect of antiinflammatory drugs in the therapy of male infertility. Fertil Steril 42:406–411PubMed

13.

Kopa Z, Wenzel J, Papp GK et al (2005) Role of granulocyte elastase and interleukin-6 in the diagnosis of male genital tract inflammation. Andrologia 37:188–194CrossRefPubMed

14.

Alvarez JG (2005) Efficient treatment of infertility due to sperm DNA damage by ICSI with testicular sperm. Hum Reprod 20:2031–2032CrossRefPubMed

15.

Ochsenkühn R, Kamischke A, Nieschlag E (1999) Imipramine for successful treatment of retrograde ejaculation caused by retroperitoneal surgery. Int J Androl 22:173–177CrossRefPubMed

16.

Kamischke A, Nieschlag E (2002) Update on medical treatment of ejaculatory disorders. Int J Androl 25:333–344CrossRefPubMed

17.

Tomasi PA, Fanciulli G, Delitala G (2005) Successful treatment of retrograde ejaculation with the alpha1-adrenergic agonist methoxamine: case study. Int J Impot Res 17:297–299CrossRefPubMed

18.

World Health Organization Task Force on the diagnosis and treatment of infertility (1989) mesterolone and idiopathic male infertility: a double-blind study. Int J Androl 12:254–264CrossRef

19.

Vandekerckhove P, Lilford R, Vail A et al (2007) Withdrawn: Androgens versus placebo or no treatment for idiopathic oligo/asthenospermia. Cochrane Database Syst Rev 18:CD000150

20.

Leschber G, Nishino Y, Neumann F (1989) Influence of an aromatase inhibitor (4-acetoxy-4-androstene-3,17-dione) on experimentally induced impairment of spermatogenesis in immature rats. Andrologia 21:529–534CrossRefPubMed

21.

Raman JD, Schlegel PN (2002) Aromatase inhibitors for male infertility. J Urol 167:624–629CrossRefPubMed

22.

Willis KJ, London DR, Bevis MA et al (1977) Hormonal effects of tamoxifen in oligospermic men. J Endocrinol 73:171–178CrossRefPubMed

23.

Krause W, Hübner HM, Wichmann U (1985) Treatment of oligozoospermia by tamoxifen: no evidence for direct testicular action. Andrologia 17:285–290CrossRefPubMed

24.

Adamopoulos DA, Pappa A, Billa E et al (2003) Effectiveness of combined tamoxifen citrate and testosterone undecanoate treatment in men with idiopathic oligozoospermia. Fertil Steril 80:914–920CrossRefPubMed

25.

Ghanem H, Shaeer O, El-Segini A (2010) Combination clomiphene citrate and antioxidant therapy for idiopathic male infertility: a randomized controlled trial. Fertil Steril 93:2232–2235CrossRefPubMed

26.

Krause W, Holland-Moritz H, Schramm P (1992) Treatment of idiopathic oligozoospermia with tamoxifen – a randomized controlled study. Int J Androl 15:14–18CrossRefPubMed

27.

Vandekerckhove P, Lilford R, Vail A et al (2007) Withdrawn: Clomiphene or tamoxifen for idiopathic oligo/asthenospermia. Cochrane Database Syst Rev 18:CD000151

28.

Glezerman M, Lunenfeld E, Potashnik G et al (1993) Efficacy of kallikrein in the treatment of oligozoospermia and asthenozoospermia: a double-blind trial. Fertil Steril 60:1052–1056PubMed

29.

Keck C, Behre HM, Jockenhövel F et al (1994) Ineffectiveness of kallikrein in treatment of idiopathic male infertility: a double-blind, randomized, placebo-controlled trial. Hum Reprod 9:325–329PubMed

30.

Vandekerckhove P, Lilford R, Vail A et al (1996) Withdrawn: Kinin-enhancing drugs for unexplained subfertility in men. Cochrane Database Syst Rev 21:CD000153

31.

Heite HG (1979) The effect of trental on spermiografic parameters, a clinical study in patients with reduced fertility. Fertil Steril 20:38–42

32.

Marrama P, Baraghini GF, Carani C et al (1985) Further studies on the effects of pentoxifylline on sperm count and sperm motility in patients with idiopathic oligo-asthenozoospermia. Andrologia 17:612–616CrossRefPubMed

33.

Wang C, Chan CW, Wong KK et al (1983) Comparison of the effectiveness of placebo, clomiphene citrate, mesterolone, pentoxifylline, and testosterone rebound therapy for the treatment of idiopathic oligospermia. Fertil Steril 40:358–365PubMed

34.

Tournaye H, Devroey P, Camus M et al (1995) Use of pentoxifylline in assisted reproductive technology. Hum Reprod 10(Suppl 1):72–79PubMed

35.

Yamamoto M, Hibi H, Miyake K (1995) Comparison of the effectiveness of placebo and alpha-blocker therapy for the treatment of idiopathic oligozoospermia. Fertil Steril 63:396–400PubMed

36.

Gregoriou O, Vitoratos N, Papadias C et al (1997) Treatment of idiopathic oligozoospermia with an alpha-blocker: a placebo-controlled double-blind trial. Int J Fertil Womens Med 42:301–305PubMed

37.

Maseki Y, Miyake K, Mitsuya H et al (1981) Mastocytosis occurring in the testes from patients with idiopathic male infertility. Fertil Steril 36:814–817PubMed

38.

Oliva A, Multigner L (2006) Ketotifen improves sperm motility and sperm morphology in male patients with leukocytospermia and unexplained infertility. Fertil Steril 85:240–243CrossRefPubMed

39.

Yamamoto M, Hibi H, Miyake K (1995) New treatment of idiopathic severe oligozoospermia with mast cell blocker: results of a single-blind study. Fertil Steril 64:1221–1223PubMed

40.

Hibi H, Kato K, Mitsui K et al (2002) Treatment of oligoasthenozoospermia with tranilast, a mast cell blocker, after long-term administration. Arch Androl 48:451–459CrossRefPubMed

41.

Cremers B, Böhm M (2003) Non erectile dysfunction application of sildenafil. Herz 28:325–333PubMed

42.

Mostafa T (2007) In vitro sildenafil citrate use as a sperm motility stimulant. Fertil Steril 88:994–996CrossRefPubMed

43.

Dimitriadis F, Tsambalas S, Tsounapi P et al (2010) Effects of phosphodiesterase-5 inhibitors on Leydig cell secretory function in oligoasthenospermic infertile men: a randomized trial. BJU Int (Epub ahead of print)

44.

Agarwal A, Saleh RA (2002) Role of oxidants in male infertility: rationale, significance, and treatment. Urol Clin North Am 29:817–827CrossRefPubMed

45.

Sanocka D, Kurpisz M (2004) Reactive oxygen species and sperm cells. Reprod Biol Endocrinol 2:12CrossRefPubMed

46.

Henkel RR, Schill WB (2003) Sperm preparation for ART. Reprod Biol Endocrinol 14:108CrossRef

47.

Lewis SE, Sterling ES, Young IS et al (1997) Comparison of individual antioxidants of sperm and seminal plasma in fertile and infertile men. Fertil Steril 67:142–147CrossRefPubMed

48.

Dawson EB, Harris WA, Rankin WE et al (1987) Effect of ascorbic acid on male fertility. Ann NY Acad Sci 498:312–323CrossRefPubMed

49.

Agarwal A, Nallella KP, Allamaneni SS et al (2004) Role of antioxidants in treatment of male infertility: an overview of the literature. Reprod Biomed Online 8:616–627CrossRefPubMed

50.

Kessopoulou E, Powers HJ, Sharma KK et al (1995) A double-blind randomized placebo cross-over controlled trial using the antioxidant vitamin E to treat reactive oxygen species associated male infertility. Fertil Steril 64:825–831PubMed

51.

Greco E, Romano S, Iacobelli M et al (2005) ICSI in cases of sperm DNA damage: beneficial effect of oral antioxidant treatment. Hum Reprod 20:2590–2594CrossRefPubMed

52.

Rolf C, Cooper TG, Yeung CH et al (1999) Antioxidant treatment of patients with asthenozoospermia or moderate oligoasthenozoospermia with high-dose vitamin C and vitamin E: a randomized, placebo-controlled, double-blind study. Hum Reprod 14:1028–1033CrossRefPubMed

53.

Comhaire FH, Christophe AB, Zalata AA et al (2000) The effects of combined conventional treatment, oral antioxidants and essential fatty acids on sperm biology in subfertile men. Prostaglandins Leukot Essent Fatty Acids 63:159–165CrossRefPubMed

54.

Taepongsorat L, Tangpraprutgul P, Kitana N et al (2008) Stimulating effects of quercetin on sperm quality and reproductive organs in adult male rats. Asian J Androl 10:249–258CrossRefPubMed

55.

Pike TW, Blount JD, Lindström J et al (2010) Dietary carotenoid availability, sexual signalling and functional fertility in sticklebacks. Biol Lett 23:191–193CrossRef

56.

Mangiagalli MG, Martino PA, Smajlovic T et al (2010) Effect of lycopene on semen quality, fertility and native immunity of broiler breeder. Br Poult Sci 51:152–157CrossRefPubMed

57.

Lenzi A, Culasso F, Gandini L et al (1993) Placebo-controlled, double-blind, cross-over trial of glutathione therapy in male infertility. Hum Reprod 8:1657–1662PubMed

58.

Lewin A, Lavon H (1997) The effect of coenzyme Q10 on sperm motility and function. Mol Aspects Med 18(Suppl):213–219CrossRef

59.

Balercia G, Mancini A, Paggi F et al (2009) Coenzyme Q10 and male infertility. J Endocrinol Invest 32:626–632PubMed

60.

Safarinejad MR (2009) Efficacy of coenzyme Q10 on semen parameters, sperm function and reproductive hormones in infertile men. J Urol 182:237–248CrossRefPubMed

61.

Dokmeci D (2005) Oxidative stress, male infertility and the role of carnitines. Folia Med (Plovdiv) 47:26–30

62.

Vicari E, Calogero AE (2001) Effects of treatment with carnitines in infertile patients with prostato-vesiculo-epididymitis. Hum Reprod 16:2338–2342PubMed

63.

Abd-Allah AR, Helal GK, Al-Yahya AA et al (2009) Pro-inflammatory and oxidative stress pathways which compromise sperm motility and survival may be altered by L-carnitine. Oxid Med Cell Longev 2:73–81CrossRefPubMed

64.

Biewenga GP, Haenen GR, Bast A (1997) The pharmacology of the antioxidant lipoic acid. Gen Pharmacol 29:315–331PubMed

65.

Ibrahim SF, Osman K, Das S et al (2008) A study of the antioxidant effect of alpha lipoic acids on sperm quality. Clinics (Sao Paulo) 63:545–550

66.

Ross C, Morriss A, Khairy M et al (2010) A systematic review of the effect of oral antioxidants on male infertility. Reprod Biomed Online 20:711–723CrossRefPubMed

67.

Patel SR, Sigman M (2008) Antioxidant therapy in male infertility. Urol Clin North Am 35:319–330CrossRefPubMed

68.

Eskenazi B, Kidd SA, Marks AR et al (2005) Antioxidant intake is associated with semen quality in healthy men. Hum Reprod 20:1006–1012CrossRefPubMed

69.

Galli F, Azzi A (2010) Present trends in vitamin E research. Biofactors 36:33–42PubMed

70.

Hogarth CA, Griswold MD (2010) The key role of vitamin A in spermatogenesis. J Clin Invest 120:956–962CrossRefPubMed

71.

Kao SH, Chao HT, Chen HW et al (2008) Increase of oxidative stress in human sperm with lower motility. Fertil Steril 89:1183–1190CrossRefPubMed

72.

Watanabe T, Ohkawa K, Kasai S et al (2003) The effects of dietary vitamin B12 deficiency on sperm maturation in developing and growing male rats. Congenit Anom (Kyoto) 43:57–61CrossRef

73.

Boxmeer JC, Smit M, Weber RF et al (2007) Seminal plasma cobalamin significantly correlates with sperm concentration in men undergoing IVF or ICSI procedures. J Androl 28:521–527CrossRefPubMed

74.

Boxmeer JC, Smit M, Utomo E et al (2009) Low folate in seminal plasma is associated with increased sperm DNA damage. Fertil Steril 92:548–556CrossRefPubMed

75.

Kvist U, Björndahl L, Kjellberg S (1987) Sperm nuclear zinc, chromatin stability, and male fertility. Scanning Microsc 1:1241–1247PubMed

76.

Marmar JL, Katz S, Praiss DE et al (1975) Semen zinc levels in infertile and postvasectomy patients and patients with prostatitis. Fertil Steril 26:1057–1063PubMed

77.

Eggert-Kruse W, Zwick EM, Batschulat K et al (2002) Are zinc levels in seminal plasma associated with seminal leukocytes and other determinants of semen quality? Fertil Steril 77:260–269CrossRefPubMed

78.

Lloyd DR, Phillips DH, Carmichael PL (1997) Generation of putative intrastrand cross-links and strand breaks in DNA by transition metal ion-mediated oxygen radical attack. Chem Res Toxicol 10:393–400CrossRefPubMed

79.

Oliva A, Dotta A, Multigner L (2009) Pentoxifylline and antioxidants improve sperm quality in male patients with varicocele. Fertil Steril 91(Suppl 4):1536–1539CrossRefPubMed

80.

Wong WY, Merkus HM, Thomas CM et al (2002) Effects of folic acid and zinc sulfate on male factor subfertility: a double-blind, randomized, placebo-controlled trial. Fertil Steril 77:491–498CrossRefPubMed

81.

Keskes-Ammar L, Feki-Chakroun N, Rebai T et al (2003) Sperm oxidative stress and the effect of an oral vitamin E and selenium supplement on semen quality in infertile men. Arch Androl 49:83–94CrossRefPubMed

82.

Iwanier K, Zachara BA (1995) Selenium supplementation enhances the element concentration in blood and seminal fluid but does not change the spermatozoal quality characteristics in subfertile men. J Androl 16:441–447PubMed

83.

Gonzales GF, Gonzales C, Gonzales-Castañeda C (2009) Lepidium meyenii (Maca): a plant from the highlands of Peru – from tradition to science. Forsch Komplementmed 16:373–380CrossRefPubMed

84.

Yucra S, Gasco M, Rubio J et al (2008) Effect of different fractions from hydroalcoholic extract of Black Maca (Lepidium meyenii) on testicular function in adult male rats. Fertil Steril 89(Suppl 5):1461–1467CrossRefPubMed

85.

Clément C, Kneubühler J, Urwyler A et al (2010) Effect of maca supplementation on bovine sperm quantity and quality followed over two spermatogenic cycles. Theriogenology 74:173–183CrossRefPubMed

86.

Comhaire FH, El Garem Y, Mahmoud A et al (2005) Combined conventional/antioxidant „Astaxanthin“ treatment for male infertility: a double blind, randomized trial. Asian J Androl 7:257–262CrossRefPubMed

87.

Stanislavov R, Nikolova V, Rohdewald P (2009) Improvement of seminal parameters with Prelox: a randomized, double-blind, placebo-controlled, cross-over trial. Phytother Res 23:297–302CrossRefPubMed

88.

D’Andrea G (2010) Pycnogenol: A blend of procyanidins with multifaceted therapeutic applications? Fitoterapia 81(7):724–736CrossRef

89.

Srivastava S, Agarwal A (2010) Effect of anion channel blockers on L-arginine action in spermatozoa from asthenospermic men. Andrologia 42:76–82CrossRefPubMed

90.

Carani C, Granata AR, De Rosa M et al (1999) The effect of chronic treatment with GH on gonadal function in men with isolated GH deficiency. Eur J Endocrinol 140:224–230CrossRefPubMed

91.

Okeahialam BN, Amadi K, Ameh AS (2006) Effect of lisnopril, an angiotensin converting enzyme (ACE) inhibitor on spermatogenesis in rats. Arch Androl 52:209–213CrossRefPubMed

92.

Byrne MM, Rolf C, Depenbusch M et al (2003) Lack of effect of a single i.v. dose of oxytocin on sperm output in severely oligozoospermic men. Hum Reprod 18:2098–2102CrossRefPubMed

93.

Seshadri S, Bates M, Vince G et al (2009) The role of cytokine expression in different subgroups of subfertile men. Am J Reprod Immunol 62:275–282CrossRefPubMed

94.

Safarinejad MR, Hosseini SY, Dadkhah F et al (2010) Relationship of omega-3 and omega-6 fatty acids with semen characteristics, and anti-oxidant status of seminal plasma: a comparison between fertile and infertile men. Clin Nutr 29:100–105CrossRefPubMed

Titel: Medikamentöse Therapiemöglichkeiten des Oligo-Astheno-Teratozoospermie-Syndroms
verfasst von: Dr. M. Trottmann
F.M. Köhn
M. Dickmann
C.G. Stief
A.J. Becker
Publikationsdatum: 01.01.2011
Verlag: Springer-Verlag
Erschienen in: Die Urologie / Ausgabe 1/2011
Print ISSN: 2731-7064
Elektronische ISSN: 2731-7072
DOI: https://doi.org/10.1007/s00120-010-2437-y

Neu im Fachgebiet Urologie

24.04.2024 | DGIM 2024 | Nachrichten

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Medikamentöse Therapiemöglichkeiten des Oligo-Astheno-Teratozoospermie-Syndroms

Zusammenfassung

Neu im Fachgebiet Urologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Varikozelen bei Jugendlichen: Das Für und Wider der Operation

Update Urologie

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2011

Qualitätssicherung bei andrologischen Operationen

Berufspolitik BDU

Die Brucellose als Differentialdiagnose zum Hodentumor

Kodierung der Zystektomie im DRG-System 2010

Hodenhochstand und Infertilität unter besonderer Berücksichtigung der interdisziplinären Leitlinie

AUO-Studie beim metastasierten Nierenzellkarzinom

Neu im Fachgebiet Urologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Varikozelen bei Jugendlichen: Das Für und Wider der Operation

Update Urologie